Femasys Inc (FEMY)
1.27
-0.02
(-1.55%)
USD |
NASDAQ |
May 17, 16:00
1.27
0.00 (0.00%)
After-Hours: 20:00
Femasys Gross Profit Margin (Quarterly): 67.35% for March 31, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 67.35% |
| December 31, 2023 | 63.26% |
| September 30, 2023 | 64.73% |
| June 30, 2023 | 65.53% |
| March 31, 2023 | 64.24% |
| December 31, 2022 | 63.52% |
| September 30, 2022 | 62.17% |
| June 30, 2022 | 66.23% |
| March 31, 2022 | 61.83% |
| Date | Value |
|---|---|
| December 31, 2021 | 74.71% |
| September 30, 2021 | 60.90% |
| June 30, 2021 | 66.99% |
| March 31, 2021 | 71.79% |
| December 31, 2020 | 68.81% |
| September 30, 2020 | 71.13% |
| June 30, 2020 | 69.83% |
| March 31, 2020 | 71.91% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
60.90%
Minimum
Sep 2021
74.71%
Maximum
Dec 2021
66.76%
Average
66.23%
Median
Jun 2022
Gross Profit Margin (Quarterly) Benchmarks
| Avinger Inc | 19.62% |
| Biolase Inc | 32.93% |
| AIM ImmunoTech Inc | 81.54% |
| Protalix BioTherapeutics Inc | 30.58% |
| Armata Pharmaceuticals Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -107.0% |
| Return on Assets | -78.29% |
| Return on Invested Capital | -94.73% |
| Profit Margin (Quarterly) | -1.33K% |
| Operating Margin (Quarterly) | -1.28K% |
| Return on Net Operating Assets | -422.8% |